BC
BCPC.US Balchem Corporation
- Market cap
- USD 5.52B
- P/E
- 32.5x
- P/B
- 4.14x
- ROE
- 13.2%
- Dividend yield
- 0.51%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BCPC.US undervalued?
Graham numberBCPC.US trades 144.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Balchem Corporation fundamental analysis
No fundamental analysis for Balchem Corporation yet.
Balchem Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Balchem Corporation
Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include sp…
Full company profileBalchem Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Balchem Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 553M | 595M | 644M | 644M | 704M | 799M | 942M | 922M | 954M | 1.04B | 1.13B |
| Gross Profit | 181M | 189M | 204M | 211M | 224M | 243M | 280M | 302M | 336M | 371M | 414M |
| Operating Income | 90.8M | 96.9M | 107M | 103M | 111M | 128M | 145M | 159M | 183M | 218M | 236M |
| EBITDA | 136M | 140M | 151M | 148M | 162M | 177M | 196M | 215M | 231M | 255M | 281M |
| Net Income | 56.0M | 90.1M | 78.6M | 79.7M | 84.6M | 96.1M | 105M | 109M | 128M | 155M | 176M |
| EPS | 1.75 | 2.79 | 2.42 | 2.45 | 2.60 | 2.94 | 3.25 | 3.35 | 3.93 | 4.75 | 5.48 |
| Balance Sheet | |||||||||||
| Total Assets | 949M | 964M | 981M | 1.16B | 1.17B | 1.20B | 1.62B | 1.60B | 1.58B | 1.69B | 1.70B |
| Total Liabilities | 428M | 347M | 290M | 412M | 338M | 322M | 686M | 543M | 425M | 429M | 377M |
| Shareholders' Equity | 521M | 617M | 692M | 744M | 828M | 877M | 938M | 1.05B | 1.15B | 1.26B | 1.33B |
| Cash & Short-term Investments | 38.6M | 40.4M | 54.3M | 65.7M | 84.6M | 103M | 66.6M | 64.4M | 49.5M | 74.6M | 66.3M |
| Total Debt | 287M | 225M | 156M | 259M | 176M | 125M | 461M | 330M | 208M | 181M | 142M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 108M | 111M | 119M | 124M | 150M | 161M | 139M | 184M | 182M | 217M | 209M |
| Capital Expenditure | 24.0M | 28.1M | 19.7M | 28.4M | 33.8M | 37.4M | 50.3M | 37.9M | 35.7M | 43.5M | 45.7M |
| Free Cash Flow | 83.6M | 82.5M | 99.0M | 96.0M | 117M | 123M | 88.2M | 146M | 146M | 173M | 209M |
| Ratios | |||||||||||
| ROE | 10.7% | 14.6% | 11.4% | 10.7% | 10.2% | 11.0% | 11.2% | 10.3% | 11.2% | 12.3% | 13.2% |
| ROA | 5.9% | 9.3% | 8.0% | 6.9% | 7.3% | 8.0% | 6.5% | 6.8% | 8.2% | 9.2% | 10.3% |
| Net Profit Margin | 10.1% | 15.1% | 12.2% | 12.4% | 12.0% | 12.0% | 11.2% | 11.8% | 13.5% | 14.9% | 15.6% |
| Debt to Equity | 0.55x | 0.36x | 0.23x | 0.35x | 0.21x | 0.14x | 0.49x | 0.31x | 0.18x | 0.14x | 0.11x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Balchem Corporation dividends
- Dividend yield
- 0.51%
- Forward dividend
- 0.96 USD
- Payout ratio
- 18.3%
- Ex-dividend date
- Dec 23, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 28.3M | 0.87 | 18.3% |
| 2024 | USD 25.6M | 0.78 | 19.9% |
| 2023 | USD 22.9M | 0.70 | 21.1% |
| 2022 | USD 20.7M | 0.64 | 19.7% |
| 2021 | USD 18.7M | 0.57 | 19.5% |
| 2020 | USD 16.7M | 0.51 | 19.7% |
| 2019 | USD 15.1M | 0.47 | 19.0% |
| 2018 | USD 13.4M | 0.41 | 17.1% |
| 2017 | USD 12.1M | 0.37 | 13.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 3:2 on Jan 21, 2010.
Who owns Balchem Corporation
- Insiders 0.49%
- Institutions 92.47%
- Public & others 7.03%
- Shares outstanding 31.9M
- Free float 31.6M
Top funds holding BCPC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 1.92M | 6.01% | -0.07% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.02M | 3.21% | +0.28% | Sep 2026 |
| iShares Russell 2000 ETF | 827K | 2.60% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 717K | 2.25% | -3.04% | Sep 2026 |
| First Trust SMID Cp Rising Div Achv ETF | 570K | 1.79% | 0.00% | Oct 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 400K | 1.25% | -5.84% | Sep 2026 |
| Fidelity Small Cap Index | 358K | 1.12% | +0.18% | Aug 2026 |
| Conestoga Small Cap Investors | 332K | 1.04% | -18.62% | Sep 2026 |
| State Street SPDR Port S&P 600 Sm CpETF | 291K | 0.91% | -0.05% | Oct 2026 |
| iShares Russell 2000 Growth ETF | 291K | 0.91% | -0.38% | Oct 2026 |
| Congress Small Cap Growth Institutional | 250K | 0.78% | 0.00% | Sep 2026 |
| Fidelity Enhanced Small Cap Core ETF | 234K | 0.73% | +0.27% | Oct 2026 |
| Vanguard Tax-Managed Small Cap Adm | 210K | 0.66% | -0.30% | Sep 2026 |
| Strategic Advisers Fidelity US TtlStk | 202K | 0.63% | +7.67% | Sep 2026 |
| Wasatch Core Growth | 197K | 0.62% | -52.12% | Sep 2026 |
| Vanguard Russell 2000 ETF | 191K | 0.60% | +1.14% | Sep 2026 |
| Vanguard Dividend Appreciation ETF | 180K | 0.57% | -0.84% | Sep 2026 |
| Vanguard Explorer Inv | 170K | 0.53% | 0.00% | Sep 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 169K | 0.53% | -0.26% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 169K | 0.53% | +0.23% | Oct 2026 |
Top institutions holding BCPC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 4.96M | 15.57% | +2.54% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 2.22M | 6.97% | +1.27% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.45M | 4.53% | +0.93% | Jun 2026 |
| State Street Corp | 1.28M | 4.02% | +3.29% | Jun 2026 |
| Geode Capital Management, LLC | 1.12M | 3.52% | +7.16% | Jun 2026 |
| Conestoga Capital Advisors, LLC | 1.09M | 3.41% | -13.05% | Jun 2026 |
| Wasatch Advisors LP | 1.05M | 3.30% | -26.18% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 834K | 2.62% | -2.67% | Jun 2026 |
| Geneva Capital Management | 683K | 2.14% | -19.30% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 639K | 2.00% | +4.69% | Sep 2026 |
| First Trust Advisors L.P. | 617K | 1.94% | +36.15% | Jun 2026 |
| FMR Inc | 560K | 1.76% | -6.42% | Jun 2026 |
| Congress Asset Management Company, LLP | 503K | 1.58% | +12.73% | Jun 2026 |
| Two Sigma Investments LLC | 502K | 1.57% | +16.70% | Jun 2026 |
| Schroder Investment Management Group | 440K | 1.38% | +22.17% | Jun 2026 |
| Nuveen, LLC | 414K | 1.30% | +5.31% | Jun 2026 |
| NORGES BANK | 412K | 1.29% | -1.57% | Jun 2026 |
| Northern Trust Corp | 384K | 1.21% | +2.72% | Jun 2026 |
| Charles Schwab Investment Management Inc | 375K | 1.18% | +1.39% | Jun 2026 |
| JPMorgan Chase & Co | 342K | 1.07% | -19.99% | Jun 2026 |
Balchem Corporation company profile
- Company name
- Balchem Corporation
- Ticker
- BCPC.US
- Exchange
- USA Stocks
- Listed since
- Jun 3, 1986
- Sector
- Basic Materials
- Industry
- Chemicals
- Employees
- 1,430
- Fiscal year end
- December
- Address
- 5 Paragon Drive, Montvale, NJ, United States, 07645
- Phone
- 845 326 5600
- Website
- balchem.com
About Balchem Corporation
Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. It sells its products through sales force, independent distributors, and sales agents. The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.
Balchem Corporation management
9- Mr. Theodore Lee HarrisCEO, President & Chairman · born 1965
- Mr. Carl Martin BengtssonExecutive VP, CFO, Treasurer and GM of Animal Nutrition & Health · born 1977
- Ms. Hatsuki Miyata J.D.Executive VP, Chief Legal Officer & Secretary · born 1976
- Mr. M. Brent TignorSenior VP & Chief Human Resources Officer · born 1978
- Mr. Frederic BonedSenior VP, Head of Digital Transformation & AI and GM of Human Nutrition & Health · born 1979
- Ms. Erin L. GilsonVP & Chief Accounting Officer
- Mr. Martin Luther ReidSenior VP & Chief Supply Chain Officer · born 1967
- Mr. Job L. van GunsterenSenior VP & GM of Specialty Products · born 1977
- Mr. George GrahamSenior VP and Chief R&D Officer · born 1970